Petition Asks For Cognitive Impairment Warning On H1 Antihistamines
This article was originally published in The Tan Sheet
Executive Summary
CHPA says existing label warnings about “marked drowsiness” sufficiently cover the risk of confusion when using the products. A petition requesting label warnings about cognitive impairment for OTCs with first-generation antihistamines or anticholinergic ingredients “raises complex issues requiring extensive review and analysis,” FDA says.
You may also be interested in...
J&J Consumer Sales Slip Even As Recalled Brands, Seasonal Items Reach Stores
J&J reports worldwide consumer sales dipped 0.6% to $3.6 billion despite retailers buying more upper respiratory and analgesic products to prepare for the cough and cold season. But in key OTC categories the firm is regaining market share it lost when its iconic brands were temporarily not available.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.
Ensuring Leading Position For GSK Consumer Products Touted In Management Shift
GlaxoSmithKline restructures its management to ensure adequate focus on its three core areas, pharmaceutical, vaccine and consumer. Consumer product sales fell 3% to $1.72 billion in the third quarter due to continuing supply interruptions and generally weaker markets.